+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dacryocystitis - Global Strategic Business Report

  • PDF Icon

    Report

  • 374 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6070754
The global market for Dacryocystitis was estimated at US$41.2 Million in 2024 and is projected to reach US$51.2 Million by 2030, growing at a CAGR of 3.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Dacryocystitis market.

Global Dacryocystitis Market - Key Trends & Growth Drivers Summarized

Why Is Dacryocystitis Becoming a Growing Concern in Ophthalmology?

Dacryocystitis, an infection or inflammation of the lacrimal sac, is becoming an increasing concern in ophthalmology due to its potential complications, including abscess formation and vision impairment. The condition is often caused by bacterial infections, trauma, or obstructions in the tear drainage system, leading to painful swelling, excessive tearing, and pus discharge. If left untreated, dacryocystitis can progress to orbital cellulitis or systemic infections, making early diagnosis and treatment essential.

The rising prevalence of age-related eye disorders, congenital tear duct obstructions in newborns, and post-surgical complications has increased the incidence of dacryocystitis. Additionally, the growing number of contact lens users and individuals undergoing aesthetic eyelid surgeries has contributed to a higher risk of tear duct infections. Advancements in minimally invasive surgical techniques and antibiotic therapies are improving patient outcomes, driving demand for effective treatment solutions.

What Are the Latest Innovations in Dacryocystitis Treatment?

The treatment of dacryocystitis has evolved with the introduction of advanced antibiotic therapies, minimally invasive procedures, and novel drug delivery systems. One of the most significant advancements is endoscopic dacryocystorhinostomy (DCR), a minimally invasive surgical procedure that creates a new tear drainage pathway without external incisions. This technique has become the preferred treatment for chronic dacryocystitis, reducing scarring and recovery time.

Additionally, the use of biodegradable drug-eluting stents is improving post-surgical outcomes by preventing tear duct re-blockage and reducing infection risks. Nanoparticle-based antibiotic eye drops are also being developed to enhance drug penetration and prolong antibacterial activity. AI-driven diagnostic tools and imaging techniques, such as dacryoscintigraphy and ultrasonography, are aiding in the early detection and personalized treatment of dacryocystitis.

How Are Market Trends and Regulatory Guidelines Influencing Dacryocystitis Treatment?

The increasing adoption of minimally invasive ophthalmic surgeries and the demand for advanced antimicrobial therapies are shaping the dacryocystitis treatment landscape. The expansion of healthcare infrastructure in developing regions has improved access to eye care services, facilitating early diagnosis and treatment of tear duct infections. Additionally, the rising geriatric population and the growing prevalence of chronic inflammatory eye conditions are fueling market demand.

Regulatory agencies, such as the U.S. FDA and the European Medicines Agency, are enforcing strict guidelines on ophthalmic drug formulations and medical devices used in dacryocystitis treatment. Compliance with sterility and biocompatibility standards is crucial for manufacturers developing antibiotic eye drops, stents, and surgical instruments. Additionally, the trend toward telemedicine and digital health platforms is enabling remote consultation and prescription management for dacryocystitis patients.

What Is Driving the Growth of the Dacryocystitis Market?

The growth in the dacryocystitis market is driven by advancements in ophthalmic surgery, increasing antibiotic-resistant infections, and rising awareness of early eye disease management. The adoption of endoscopic DCR and non-invasive drug delivery systems is improving treatment outcomes while minimizing complications.

End-use expansion is another critical factor, with dacryocystitis treatment becoming a focus in pediatric ophthalmology, post-surgical eye care, and geriatric medicine. The integration of AI and machine learning in ophthalmic diagnostics is also enhancing the accuracy of tear duct assessments. Additionally, the development of personalized treatment approaches, including patient-specific antibiotic regimens and customized surgical techniques, is shaping the future of dacryocystitis management. As ophthalmic research continues to advance, the dacryocystitis market is expected to grow steadily, supporting innovations in eye infection treatment and surgical care.

Scope of Study:

The report analyzes the Dacryocystitis market in terms of units by the following Segments, and Geographic Regions/Countries:
  • Segments: Treatment Type (Surgical Treatment, Medication Treatment); Indication (Chronic Dacryocystitis Treatment, Acute Dacryocystitis Treatment, Congenital Dacryocystitis Treatment); Sales Channel (Institutional Sales Channel, Retail Sales Channel)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Surgical Treatment segment, which is expected to reach US$27.7 Million by 2030 with a CAGR of a 4.6%. The Medication Treatment segment is also set to grow at 2.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $11.2 Million in 2024, and China, forecasted to grow at an impressive 7.0% CAGR to reach $10.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Dacryocystitis Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Dacryocystitis Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Dacryocystitis Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Alcon Inc., Aurobindo Pharma Limited, Aurolab, Bausch Health Companies Inc., Bayer AG and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 47 companies featured in this Dacryocystitis market report include:

  • Alcon Inc.
  • Aurobindo Pharma Limited
  • Aurolab
  • Bausch Health Companies Inc.
  • Bayer AG
  • Beaver-Visitec International
  • Bess Medizintechnik GmbH
  • BVM Medical Limited
  • F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • FCI Ophthalmics (part of ZEISS Group)
  • Fruida
  • GlaxoSmithKline plc
  • Gunther Weiss Scientific Glassblowing Co., Inc.
  • Kaneka Corporation
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris Inc.)
  • Nosch Labs Pvt Ltd
  • Orex Pharma Pvt Ltd
  • Pfizer Inc.
  • Sinopsys Surgical

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Dacryocystitis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Chronic and Acute Tear Duct Infections Elevating Diagnosis Rates
  • Growth in Elderly Population Driving Susceptibility to Lacrimal Disorders
  • Rising Adoption of Minimally Invasive Dacryocystorhinostomy (DCR) Procedures
  • Technological Advancements in Endoscopic and Laser-Assisted Surgeries
  • Use of Imaging and Diagnostic Tools Enhancing Early Detection and Classification
  • Expanding Access to Ophthalmic Care in Emerging Economies Supporting Treatment Volumes
  • Wider Use of Broad-Spectrum Antibiotics Driving First-Line Management Options
  • Increased Availability of Tear Drainage Stents and Implants Improving Recovery Outcomes
  • Integration of Dacryocystitis Screening in Routine Eye Examinations Boosting Awareness
  • Growing Training and Expertise in Oculoplastic Surgery Enhancing Surgical Success Rates
  • Emergence of Single-Use and Disposable Surgical Instruments Supporting Infection Control
  • Use of Culture-Guided Therapy in Recurrent Cases Enhancing Treatment Efficacy
  • Increased Awareness Among Primary Care Providers Promoting Referrals
  • Growth in Pediatric Cases Leading to Improved Early Intervention Techniques
  • Innovations in Topical and Injectable Therapies Driving Outpatient Treatment Adoption
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dacryocystitis Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dacryocystitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dacryocystitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Dacryocystitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Surgical Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Surgical Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Surgical Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Medication Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Chronic Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Chronic Dacryocystitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Acute Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Acute Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Acute Dacryocystitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Congenital Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Congenital Dacryocystitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Congenital Dacryocystitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Institutional Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Institutional Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Institutional Sales Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Retail Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Retail Sales Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Retail Sales Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • CANADA
  • JAPAN
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • CHINA
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • EUROPE
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • FRANCE
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • GERMANY
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • ITALY
  • UNITED KINGDOM
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • AUSTRALIA
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • INDIA
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Dacryocystitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alcon Inc.
  • Aurobindo Pharma Limited
  • Aurolab
  • Bausch Health Companies Inc.
  • Bayer AG
  • Beaver-Visitec International
  • Bess Medizintechnik GmbH
  • BVM Medical Limited
  • F. Hoffmann-La Roche Ltd (Genentech, Inc.)
  • FCI Ophthalmics (part of ZEISS Group)
  • Fruida
  • GlaxoSmithKline plc
  • Gunther Weiss Scientific Glassblowing Co., Inc.
  • Kaneka Corporation
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris Inc.)
  • Nosch Labs Pvt Ltd
  • Orex Pharma Pvt Ltd
  • Pfizer Inc.
  • Sinopsys Surgical

Table Information